HemOnc Today Current Issue
The following articles appeared in the print edition of HemOnc Today.
Table of Contents
- Rapid changes, critical unknowns in cancer care amid COVID-19 Jennifer R. Southall
-
- Cancer care after COVID-19 John Sweetenham, MD, FRCP, FACP
- COVID-19 pandemic prompts emergency radiation therapy guidelines for hematologic malignancies Jennifer Byrne
- Lung cancer management in the COVID-19 era requires an individualized approach Jennifer R. Southall
- Mortality rates decline among adolescent, young adult cancer survivors John DeRosier
- Apixaban noninferior to dalteparin for cancer-related VTE treatment Darlene Dobkowski, MA
- Targeted conditioning improves transplant rate for relapsed, refractory AML John DeRosier
- HSCT after quizartinib or chemotherapy extends OS in AML subset John DeRosier
- Duration of remission predictive of second HSCT in pediatric leukemia, myelodysplastic syndrome John DeRosier
-
- Timing, patterns of relapse predict survival after HSCT for multiple myeloma Mark Leiser
- LentiGlobin gene therapy shows promise for severe sickle cell disease Mark Leiser
- Survey shows significant gender pay gap in gynecologic oncology Jennifer R. Southall
- Adjuvant HPV vaccination lowers risk for high-grade cervical dysplasia recurrence Jennifer R. Southall
- Bias, stereotypes may play role in cancer clinical trial enrollment Jennifer R. Southall
- Nivolumab shows limited activity in untreated brain metastases from renal cell carcinoma John DeRosier
- Cannabinoids ineffective for cancer pain Jennifer R. Southall
- Researchers report ‘large shift’ in colorectal cancer burden to younger adults John DeRosier; Mark Leiser
-
- FDA approves Opdivo-Yervoy combination for previously treated hepatocellular carcinoma
- FDA approves Braftovi with Erbitux for metastatic colorectal cancer subset
- FDA grants priority review to Ryoncil for certain children with acute GVHD
- FDA approves Imfinzi for extensive-stage small cell lung cancer
- FDA grants fast track status to several agents
- FDA grants priority review to cancer therapies
- Two therapies receive orphan drug status
- Venetoclax regimen fails to extend OS in newly diagnosed AML
-
- Selinexor regimen extends PFS in pretreated multiple myeloma
- Adjuvant osimertinib shows ‘overwhelming efficacy’ for EGFR-mutated lung cancer
- Physicians receive awards for service to patients near end of life
- NCI awards $8.3 million for research into prevention of HPV-related cancers
- Memorial Sloan Kettering Cancer Center announces appointments
- Parker Institute for Cancer Immunotherapy awards grants to six early career researchers
- Roswell Park department chair receives award from Weill Cornell
- Cancer researcher becomes The US Oncology Network’s chief scientific officer
-